Opyl Ltd. (AU:PKY)
ASX:PKY
Want to see AU:PKY full AI Analyst Report?
PKY Stock Chart & Stats
AU$0.03
--
Market closed
AU$0.03
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.07
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.13M
Market Cap
AU$24.89M
Enterprise ValueAU$14.22M
Total Cash (Recent Filing)AU$580.84K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding607,077,760
10 Day Avg. Volume406,454
30 Day Avg. Volume1,132,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-21.63
Price to Sales (P/S)208.90
P/FCF Ratio-4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-driven Clinical Trial PlatformOpyl’s core focus on AI/ML for clinical trials is a durable strategic asset: algorithmic platforms can create defensible data moats and recurrent utility for sponsors, improving patient ID and trial efficiency. Over months this supports sticky B2B relationships and product-led scaling.
Diverse B2B Revenue Model PotentialThe company’s explicit mix of subscriptions, consulting services, and partnership/milestone structures provides multiple durable monetisation paths. This diversity can stabilise cash flow as platform adoption grows and enables hybrid recurring and project revenue over a multi-month horizon.
Lean Operating StructureA very small headcount indicates a capital-efficient, software-led cost base that can preserve runway and enable rapid product iteration. For a platform business, low fixed payroll overhead supports slower cash burn pacing and flexible resource allocation while pursuing customer wins.
Bears Say
Severe Revenue ContractionAn ~86% year‑over‑year revenue drop is structurally damaging: it reduces commercial traction, undermines recurring revenue baselines, and lengthens the path to scale. Recovery will likely require sustained new sales or partnerships, increasing funding needs over months.
Persistent Losses And Negative MarginsConsistent negative gross and operating margins indicate the business is not yet economically viable. Ongoing unprofitability constrains reinvestment in product and sales, raises refinancing risk, and can deter enterprise customers and partners over a 2–6 month horizon without a credible remediation plan.
Negative Equity And Fragile Balance SheetNegative shareholders’ equity and rising debt create structural funding vulnerability. A thin asset base limits collateral and increases dilution or refinancing risk if cash burn continues, reducing strategic flexibility and making sustained investment or large partnerships harder to secure.
Opyl Ltd. News
PKY FAQ
What was Opyl Ltd.’s price range in the past 12 months?
Opyl Ltd. lowest share price was AU$0.01 and its highest was AU$0.07 in the past 12 months.
What is Opyl Ltd.’s market cap?
Opyl Ltd.’s market cap is AU$24.89M.
When is Opyl Ltd.’s upcoming earnings report date?
Opyl Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 98 days.
How were Opyl Ltd.’s earnings last quarter?
Opyl Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Opyl Ltd. overvalued?
According to Wall Street analysts Opyl Ltd.’s price is currently Overvalued.
Does Opyl Ltd. pay dividends?
Opyl Ltd. does not currently pay dividends.
What is Opyl Ltd.’s EPS estimate?
Opyl Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opyl Ltd. have?
Opyl Ltd. has 607,077,760 shares outstanding.
What happened to Opyl Ltd.’s price movement after its last earnings report?
Opyl Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Opyl Ltd.?
Currently, no hedge funds are holding shares in AU:PKY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opyl Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.74%
12-Months-Change
Fundamentals
Return on Equity
-1122.02%
Trailing 12-Months
Asset Growth
129.09%
Trailing 12-Months
Company Description
Opyl Ltd.
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process. The company serves biopharma, MedTech, government, and healthcare organizations. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025. Pathkey.AI Ltd was incorporated in 1994 and is based in Sydney, Australia.
Technical Analysis
Global Health Limited
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
InteliCare Holdings Limited
―
Options Prices
Currently, No data available
---